Recent Publications

Qian DC, Sykes-Martin KD, Tobillo R, Ali N, Wynne JF, Eaton BR, Paulino AC, Kalapurakal JA, Esiashvili N Impact of Age on Overall Survival Among Children With Wilms Tumor: A Population-based Registry Analysis. Am J Clin Oncol 2023 Mar 01;. doi:10.1097/COC.0000000000000990
Zou H, Poore B, Brown EE, Qian J, Xie B, Asimakidou E, Razskazovskiy V, Ayrapetian D, Sharma V, Xia S et al. A neurodevelopmental epigenetic programme mediated by SMARCD3-DAB1-Reelin signalling is hijacked to promote medulloblastoma metastasis. Nat Cell Biol 2023 Mar;25(3):493-507. doi:10.1038/s41556-023-01093-0
Logun M, Colonna MB, Mueller KP, Ventarapragada D, Rodier R, Tondepu C, Piscopo NJ, Das A, Chvatal S, Hayes HB et al. Label-free in vitro assays predict the potency of anti-disialoganglioside chimeric antigen receptor T-cell products. Cytotherapy 2023 Feb 25;. pii:S1465-3249(23)00026-9
Abdallah AS, Cardona HJ, Gadd SL, Brat DJ, Powla PP, Alruwalli WS, Shen C, Picketts DJ, Li XN, Becher OJ Novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of Hoxa cluster genes and promotion of neuronal lineage. Neurooncol Adv 2023;5(1):vdad003. pii:vdad003
Liang J, Fang D, Gumin J, Najem H, Sooreshjani M, Song R, Sabbagh A, Kong LY, Duffy J, Balyasnikova IV et al. A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin. Cancers (Basel) 2023 Feb 08;15(4). pii:1085
Rice SR, Chhabra AM, Holtzman A, Isabelle Choi J, Hasan S, Press RH, Chang J, Halasz L, Tsai HK, Jake Wang C et al. Clinical outcomes and toxicities of 100 patients treated with proton therapy for chordoma on the Proton Collaborative Group Prospective Registry. Radiother Oncol 2023 Feb 20;:109551. doi:10.1016/j.radonc.2023.109551
Raue KD, Duffy JT, Babak MV, Balyasnikova IV Modeling glioblastoma complexity with organoids for personalized treatments. Trends Mol Med 2023 Apr;29(4):282-296. doi:10.1016/j.molmed.2023.01.002
Ellingwood A, Wan H, Lee-Chang C, Lesniak MS, Zhang P Therapeutic Nanoparticles Harness Myeloid Cells for Brain Tumor-targeted Delivery and Immunomodulation. Mat Matters (Milwaukee) 2022;17(2):29-36
Qi L, Lindsay H, Kogiso M, Du Y, Braun FK, Zhang H, Guo L, Zhao S, Injac SG, Baxter PA et al. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest 2022 Feb;102(2):185-193. doi:10.1038/s41374-021-00700-8
Zhao Q, Hu J, Kong L, Jiang S, Tian X, Wang J, Hashizume R, Jia Z, Fowlkes NW, Yan J et al. FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nat Commun 2023 Feb 10;14(1):735. pii:735
Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM et al. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer 2023 Feb;11(2). pii:e006239
Lee-Chang C, Lesniak MS Next-generation antigen-presenting cell immune therapeutics for gliomas. J Clin Invest 2023 Feb 01;133(3). pii:e163449
Petrosyan E, Fares J, Fernandez LG, Yeeravalli R, Dmello C, Duffy JT, Zhang P, Lee-Chang C, Miska J, Ahmed AU et al. Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. Mol Cancer Res 2023 Jan 18;. pii:MCR-22-0920
Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest 2023 Jan 17;133(2). pii:e163447
Zhang S, Zhang T, He Z, Li X, Zhang L, Zhu D, Jiang X, Liu T, Han J, Guo L Gyral peaks and patterns in human brains. Cereb Cortex 2023 Jan 16;. pii:bhac537
Shonka NA, Horbinski CM Reconciling the Contemporary Molecular Diagnosis of Glioblastoma With Past Clinical Trial Data. JCO Oncol Pract 2023 Jan 13;:OP2200784. doi:10.1200/OP.22.00784
Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S et al. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw 2023 Jan;21(1):12-20. doi:10.6004/jnccn.2023.0002
Shah AN, Santa-Maria CA, Mukhija D, Shah N, Kang AK, Kumthekar P, Burdett K, Chandra S, Chang J, Tsarwhas D et al. A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases. Clin Breast Cancer 2022 Dec 15;. pii:S1526-8209(22)00283-X
Sasaki T, Watanabe J, He X, Katagi H, Suri A, Ishi Y, Abe K, Natsumeda M, Frey WH, Zhang P et al. Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma. J Neurosurg 2022 Nov 11;:1-10. doi:10.3171/2022.9.JNS22715
Miska J, Chandel NS Targeting fatty acid metabolism in glioblastoma. J Clin Invest 2023 Jan 03;133(1). pii:e163448
Wang X, Li Z, Sun R, Li X, Guo R, Cui X, Liu B, Li W, Yang Y, Huang X et al. Zunyimycin C enhances immunity and improves cognitive impairment and its mechanism. Front Cell Infect Microbiol 2022;12:1081243. pii:1081243
Fenton SE, Zannikou M, Ilut L, Fischietti M, Ji C, Oku CV, Horvath CM, Le Poole IC, Bosenberg M, Bartom ET et al. Targeting ULK1 decreases interferon-γ-mediated resistance to immune checkpoint inhibitors. Mol Cancer Res 2022 Dec 27;. pii:MCR-22-0684
Kros JM, Rushing E, Uwimana AL, Hernández-Laín A, Michotte A, Al-Hussaini M, Bielle F, Mawrin C, Marucci G, Tesileanu CMS et al. Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033. Neuro Oncol 2022 Dec 26;. pii:noac282
Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, Ruhl J, Waite K, Negoita S, Hofferkamp J et al. Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol 2023 Feb 14;25(2):424-429. doi:10.1093/neuonc/noac270
Varela ML, Comba A, Faisal SM, Argento A, Franson A, Barissi MN, Sachdev S, Castro MG, Lowenstein PR Gene Therapy for High Grade Glioma: The Clinical Experience. Expert Opin Biol Ther 2023 Feb;23(2):145-161. doi:10.1080/14712598.2022.2157718
Adekanmbi A, Youngblood MW, Karras CL, Oyetunji EA, Kalapurakal J, Horbinski CM, Najem H, Hill VB, Chandler JP, Heimberger AB et al. Clinical Management of Supratentorial Non-Skull Base Meningiomas. Cancers (Basel) 2022 Nov 29;14(23). pii:5887
McAleer MF, Melchior P, Parkes J, Pater L, Rübe C, Saunders D, Paulino AC, Janssens GO, Kalapurakal J Harmonica consensus, controversies, and future directions in radiotherapy for pediatric Wilms tumors. Pediatr Blood Cancer 2022 Dec 08;:e30090. doi:10.1002/pbc.30090
McCord M, Bartom E, Burdett K, Baran A, Eckerdt FD, Balyasnikova IV, McCortney K, Sears T, Cheng SY, Sarkaria JN et al. Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. Cancers (Basel) 2022 Nov 09;14(22). pii:5494
Abraham CD, Pugh SL, Bovi JA, Gondi V, Mehta MP, Benzinger T, Owen CJ, Lo SS, Kundapur V, Brown PD et al. Association of Pretreatment Hippocampal Volume With Neurocognitive Function in Patients Treated With Hippocampal Avoidance Whole Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology/RTOG 0933. Adv Radiat Oncol 2022;7(6):100859. pii:100859
Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC et al. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma. J Med Chem 2022 Dec 08;65(23):15642-15662. doi:10.1021/acs.jmedchem.2c00771
Burdett KB, Unruh D, Drumm M, Steffens A, Lamano J, Judkins J, Schwartz M, Javier R, Amidei C, Lipp ES et al. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023 Mar 16;141(11):1322-1336. doi:10.1182/blood.2022017858
Lukas RV, Chmura SJ, Parney IF, Mammoser A, Smith SM, Li J Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting. Neurooncol Pract 2022 Dec;9(6):552-558. doi:10.1093/nop/npac071
Fischietti M, Eckerdt F, Perez RE, Guillen Magaña JN, Mazewski C, Ho S, Gonzalez C, Streich LD, Beauchamp EM, Heimberger AB et al. SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression. Cancer Res Commun 2022 Sep;2(9):966-978. doi:10.1158/2767-9764.crc-22-0192
Seliger C, Oppong FB, Lefranc F, Chinot O, Stupp R, Nabors B, Gorlia T, Weller M, Association of antidepressant drug use with outcome of patients with glioblastoma. Int J Cancer 2023 Apr 01;152(7):1348-1359. doi:10.1002/ijc.34344
Matsui JK, Perlow HK, Facer BD, McCalla A, Marrazzo L, Detti B, Scorsetti M, Clerici E, Scoccianti S, Navarria P et al. Radiotherapy for elderly patients with glioblastoma: an assessment of hypofractionation and modern treatment techniques. Chin Clin Oncol 2022 Oct;11(5):38. doi:10.21037/cco-22-76
Zhao S, Li J, Zhang H, Qi L, Du Y, Kogiso M, Braun FK, Xiao S, Huang Y, Li J et al. Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. Nat Commun 2022 Nov 05;13(1):6689. pii:6689
Tripathi S, Najem H, Mahajan AS, Zhang P, Low JT, Stegh AH, Curran MA, Ashley DM, James CD, Heimberger AB cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. F1000Res 2022;11:1010. pii:1010
Karras CL, Texakalidis P, Nie JZ, Trybula SJ, Youngblood MW, Sachdev S, Thomas TO, Kalapurakal J, Chandler JP, Magill ST Outcomes following stereotactic radiosurgery for foramen magnum meningiomas: a single-center experience and systematic review of the literature. Neurosurg Focus 2022 Nov;53(5):E6. doi:10.3171/2022.8.FOCUS22299
Pohling C, Nguyen H, Chang E, Schubert KE, Nie Y, Bashkirov V, Yamamoto V, Zeng Y, Stupp R, Schulte RW et al. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. Bioelectrochemistry 2023 Feb;149:108287. doi:10.1016/j.bioelechem.2022.108287
Mo Y, Duan S, Zhang X, Hua X, Zhou H, Wei HJ, Watanabe J, McQuillan N, Su Z, Gu W et al. Epigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4. Cancer Discov 2022 Dec 02;12(12):2906-2929. doi:10.1158/2159-8290.CD-21-1492
Zhao G, Newbury P, Ishi Y, Chekalin E, Zeng B, Glicksberg BS, Wen A, Paithankar S, Sasaki T, Suri A et al. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma. Acta Neuropathol Commun 2022 Oct 23;10(1):150. pii:150
Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H, Nasrallah MP et al. Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathol 2023 Jan;145(1):71-82. doi:10.1007/s00401-022-02513-5
Ghochani Y, Muthukrishnan SD, Sohrabi A, Kawaguchi R, Condro MC, Bastola S, Gao F, Qin Y, Mottahedeh J, Iruela-Arispe ML et al. A molecular interactome of the glioblastoma perivascular niche reveals integrin binding sialoprotein as a mediator of tumor cell migration. Cell Rep 2022 Oct 18;41(3):111511. doi:10.1016/j.celrep.2022.111511
Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L et al. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol 2023 Feb 20;41(6):1285-1295. doi:10.1200/JCO.22.00164
Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS et al. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 2023 Jan 05;25(1):4-25. doi:10.1093/neuonc/noac207
Dajani S, Hill VB, Kalapurakal JA, Horbinski CM, Nesbit EG, Sachdev S, Yalamanchili A, Thomas TO Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy. J Clin Med 2022 Oct 10;11(19). pii:5961
Jamshidi P, Brat DJ The 2021 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol 2022 Dec 01;35(6):764-771. doi:10.1097/WCO.0000000000001109
Kumthekar P, Grimm SA, Aleman RT, Chamberlain MC, Schiff D, Wen PY, Iwamoto FM, Gursel DB, Reardon DA, Purow B et al. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv 2022;4(1):vdac123. pii:vdac123
Seol SW, Lee BH, Sita TL, Devineni JR, Kruser TJ, Sachdev S, Gentile M, Helenowski I, Mittal BB Hippocampus sparing volumetric modulated arc therapy in patients with loco-regionally advanced oropharyngeal cancer. Phys Imaging Radiat Oncol 2022 Oct;24:71-75. doi:10.1016/j.phro.2022.09.008
Zhang Y, Nguyen CC, Zhang NT, Fink NS, John JD, Venkatesh OG, Roe JD, Hoffman SC, Lesniak MS, Wolinsky JP et al. Neurological Applications of Belzutifan in von Hippel Lindau Disease. Neuro Oncol 2022 Oct 10;. pii:noac234

These are the publications from our team members that have been most recently indexed by PubMed. Visit PubMed to see more of our publications.